The North America NGS-based RNA-sequencing market is experiencing robust growth fueled by technological advancements, increased research activities, and rising adoption in clinical diagnostics across the region. With leading companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies driving innovation and partnerships, the market is set for substantial expansion. The market was valued at USD 1325 Million in 2025 and is projected to reach USD 4960 Million by 2035, growing at a CAGR of 14.1% from 2024 to 2035.
The economic impact of tariffs on "North America NGS-based RNA-sequencing Market".
Market Growth Drivers
Rising Adoption of Precision Medicine: The increasing emphasis on personalized healthcare and precision medicine has significantly accelerated the demand for advanced sequencing technologies, including NGS-based RNA-sequencing. Companies such as Illumina are leading this trend by developing solutions tailored to clinical research and diagnostics, allowing for more accurate disease profiling and targeted therapies. With regulatory support and increased funding for precision medicine initiatives in North America, the application of RNA-seq is rapidly expanding among healthcare providers and research institutions.
Technological Advancements and Cost Reduction: Continuous improvements in sequencing platforms and bioinformatics tools have significantly lowered the cost and turnaround time for RNA-sequencing. Thermo Fisher Scientific’s Ion Torrent and Agilent Technologies’ comprehensive RNA-seq kits have democratized access for laboratories of all sizes. The integration of automation and cloud-based data analysis has further streamlined workflows, boosting the adoption rate among academic, biopharmaceutical, and clinical research labs.
Market Trends
Integration of AI and Machine Learning in Data Analysis: The handling and interpretation of vast RNA-seq datasets have been transformed by AI-driven analytics. Companies like Qiagen and Illumina are incorporating machine learning algorithms into their platforms to enhance biomarker discovery, differential expression analysis, and disease classification. This trend is helping researchers better understand complex biological processes, leading to faster and more accurate scientific discoveries.
Expansion of Single-Cell RNA-sequencing: The growing interest in single-cell RNA-seq (scRNA-seq) applications is another dominant trend. 10x Genomics has pioneered high-throughput scRNA-seq platforms, enabling researchers to profile gene expression at the resolution of individual cells. This development allows unprecedented insights into cellular heterogeneity, driving new discoveries in oncology, immunology, and developmental biology.
Market Opportunity
Clinical Diagnostics for Cancer and Rare Diseases: With the increasing prevalence of cancer and rare genetic disorders in North America, NGS-based RNA-sequencing offers significant opportunities for the development of diagnostic and prognostic assays. Illumina and other market leaders are collaborating with health networks to introduce RNA-seq based diagnostics into routine clinical practice.
Growth of RNA-based Therapeutics Research: The surge in research initiatives focused on RNA-based therapeutics, including mRNA vaccines and gene therapy, creates lucrative opportunities. Companies like BioNTech are investing in RNA-seq to accelerate target identification, drug discovery, and development.
North America NGS-based RNA-sequencing Market Revenue (USD Million), 2020-2035
The market revenue chart indicates a strong upward trend in the North American NGS-based RNA-sequencing market from 2020 to 2035. The data shows steady growth in the initial years, with a significant acceleration post-2025, attributed to technological advancements, greater adoption in clinical diagnostics, and robust research funding. By 2035, the market is projected to reach nearly USD 4960 Million, highlighting the increasing reliance on NGS-based RNA-seq in genomic medicine, drug discovery, and translational research across the region.
North America NGS-based RNA-sequencing Market by Regional Share (%), 2025
In 2025, the United States dominates the North America NGS-based RNA-sequencing market with a commanding share of 78%, reflecting its strong infrastructure, key research institutions, and presence of global sequencing technology leaders. Canada follows with 16%, benefiting from growing research investments and healthcare innovations, while Mexico accounts for 4% as it ramps up genomics capabilities. Together, other North American territories comprise 2% of the market. The pie chart emphasizes the pivotal role of the U.S. in driving the region’s market dynamics and technological adoption.
Recent Market Developments (Past 6 Months)
In March 2024, Illumina Inc. launched the NovaSeq X Plus platform in North America, including advanced RNA-seq applications. The new system offers cost-effective, ultra-high-throughput sequencing, catering to increasing demand from translational research and clinical labs. With integrated AI-based data analysis partnerships, this launch aims to accelerate discoveries in oncology and neurology.
In January 2024, Thermo Fisher Scientific and Genentech announced a collaborative research initiative focused on developing NGS-based RNA-sequencing solutions for immune-oncology applications. The partnership will leverage Thermo Fisher’s Ion Torrent platform to enable biomarker discovery, supporting the next generation of personalized cancer immunotherapies across North America.
In February 2024, Agilent Technologies acquired a Boston-based bioinformatics company specializing in cloud-based RNA-seq analysis pipelines. This acquisition is set to enhance Agilent’s end-to-end workflow solutions and expand its presence in the rapidly evolving market for clinical genomics data management, analytics, and clinical NGS applications.
By Type: mRNA Sequencing, miRNA Sequencing, De novo Transcriptome Assembly, Small RNA Sequencing, Whole Transcriptome Sequencing, Targeted RNA Sequencing; By Application: Diagnostics, Drug Discovery, Biomarker Discovery, Toxicogenomics, Personalized Medicine, Others
Press Releases